Pyxis Oncology, Inc.
Price Action
Technical Summary
CONSOLIDATINGPyxis Oncology, Inc. is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is leading (RS Rating: 93), indicating clear outperformance against the broad market. Earnings contraction of 6% provides fundamental context to the price action. However, price is extended 30% above the 50-day line, increasing the risk of a mean reversion.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $2.11 | +24.73% | ABOVE |
| 50 SMA | $2.03 | +29.52% | ABOVE |
| 100 SMA | $1.76 | +49.27% | ABOVE |
| 150 SMA | $1.98 | +32.77% | ABOVE |
| 200 SMA | $2.33 | +12.94% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is PYXS in an uptrend right now?
PYXS has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is PYXS overbought or oversold?
PYXS's RSI (14) is 73. The stock is in overbought territory (RSI > 70), which may signal a pullback.
Is PYXS outperforming the market?
PYXS has a Relative Strength (RS) Rating of 93 out of 99. Yes, PYXS is a market leader, outperforming 93% of all stocks over the past 12 months.
Where is PYXS in its 52-week range?
PYXS is trading at $2.63, which is 47% of its 52-week high ($5.55) and 36% above its 52-week low ($0.97).
How volatile is PYXS?
PYXS has a Beta of 1.24 and 52-week volatility of 120%. It's more volatile than the S&P 500 - expect bigger swings.